Aethlon Medical Granted Full Ethics Approval for Hemopurifier Cancer Trial
WEB Aethlon Medical Receives Second Ethics Committee Approval for Hemopurifier Cancer Trial
US-based medical therapeutic company Aethlon Medical has received full ethics approval from the Human Research Ethics Committee at Central Adelaide Local Health Network in Australia for its Hemopurifier Cancer Trial. This is the second ethics approval Aethlon has received for the trial, following approval from the Bellberry Human Research Ethics Committee in June 2024.
About Aethlon Medical and the Hemopurifier Cancer Trial
Aethlon Medical is a medical therapeutic company focused on developing innovative treatments for cancer and infectious diseases. The Hemopurifier Cancer Trial is investigating the safety and efficacy of Aethlon's Hemopurifier in removing cancer cells and tumor-derived exosomes from the bloodstream. The trial is expected to enroll up to 20 patients with advanced solid tumors.
The Hemopurifier is a device that uses a novel filtration technology to remove cancer cells and tumor-derived exosomes from the bloodstream. Exosomes are small vesicles that are released by cancer cells and contain proteins, lipids, and nucleic acids that can promote tumor growth and metastasis.
Conclusion
The full ethics approval from the Human Research Ethics Committee at Central Adelaide Local Health Network is a significant milestone for Aethlon Medical and its Hemopurifier Cancer Trial. This approval allows Aethlon to proceed with the trial and evaluate the safety and efficacy of its Hemopurifier in removing cancer cells and tumor-derived exosomes from the bloodstream. The trial is expected to provide valuable data that could lead to the development of a new treatment option for patients with advanced solid tumors.
Comments